
PATENT Docket No. 350013-71



## RECEIVED

FEB 2 8 2001 TECH CENTER 1600/2900

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application Of:

Colin Watts

**Serial Number:** 09/646,950

Filing Date: December 8, 2000

Entitled: USE OF INHIBITORS OF

MAMMALIAN ASPARAGINYL ENDOPEPTIDASE FOR THERAPY OF AUTOIMMUNE DISEASE

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed on the attached Form PTO-1449 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the cited documents are enclosed. References AF, AG, FI, GA, GB, GC, GD, GE and GF are herein disclosed for the first time. Applicant previously filed an Information Disclosure Statement listing all other enclosed documents as being "on order".

 $\circ$ 

SERIAL NO.: 09/646,950



DOCKET NO. 350013-71

The filing of this Supplemental Information Disclosure Statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), as an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this Supplemental Information Disclosure Statement shall not be construed as an admission against interest in any manner.

## **CONCLUDING REMARKS**

It is respectfully requested that the examiner indicate consideration of the cited references by returning a copy of the attached form PTO-1449 with initials or other appropriate marks with the initial Office Action, and that the references be made of record as cited references in the application.

Respectfully submitted,

Date: February 21, 2001

Spyros J. Lazaris

Registration No. 45,981

OPPENHEIMER WOLFF & DONNELLY LLP

2029 Century Park East, 38th Floor Los Angeles, CA 90067-3024

Telephone: (310) 788-5000 Facsimile: (310) 788-5100 RECEIVED

TECH CENTER 1600/2900

			O	- 5			T = - : : : : : : : : : : : : : : : : : :	
		1449 (Modified)		Doget No.:			Serial No.	: 09/646,950
LIST C	F PAT	ENTS AND PUB	LICATIONS	Applicants:	Colin Wat	ts		
		ANT'S INFORMA E STATEMENT	TION					
חוססב		LOTATEMENT	-	Filing Date:	Sept. 25, 2	2000	Art Unit:	
		UI	NITED STATE				<u> </u>	
*Exr's.	Ref.	Patent No.	Date	Name Class			Sub Class	Filing Date
Inits.		<u> </u>	* 0					(if applic- able)
	AA							
	AB						<u> </u>	
			FOREIGN P					
Exr's. Init.	Ref	Document No.	Date	Country	Class	Sub	Yes	inslation? No
	AC	WO 91/06571	16.05.91	PCT				
	AD	WO 94/24281	27.10.94	PCT				
-	AE	WO 97/40066	30.10.97	PCT				
	AF	EP 0430645B1	27.11.90	EPO				
	AG	EP 0478602B1	20.06.90	EPO				
	ОТІ	HER REFERENC	ES (Including	Author, D	ate, Title, F	Pertiner	nt Pages, E	tc.)
Exr's. Inits.	Ref.	ef. Bibliographic Data						
	AH	Agrawal, Sudhi Pharmacokinet phosphorothioa	ics, biodistribu	ition, and sta	ability of olig	godeox	ynucleotide	,
	Al	Xiao, Bao-Guo Prevent and Tr IMMUNOPATH	eat Autoimmu	ne Diseases	; CLINICAI	_ IMMU	NOLOGY A	
	AJ	Altmann, Daniel M., et al.; March, 1995; The T Cell Response of HLA-DR Transgenic Mice to Human Myelin Basic Protein and Other Antigens in the Presence and Absence of Human CD4; TRANSPLANTATION BIOLOGY; pp. 867- 875						the
	AK	Fineschi, Beatr processing; EL					al proteases	s and antigen
	AL	Agrawal, Sudh and phosphoro PROC.NATL.A	thioates as inl	hibitors of hu	ıman immu	nodefic		amidates
Examir	ner				Date Cons	sidered	,	
609. D	raw lir	nitial if citation con ne through citation orm with next com	n (i.e., <del>citation</del> )	if not in cor	itation is in Iformance a	conforn and not	nance with I considered	M.P.E.P. ¶ Linclude EIVED

FEB 2 8 2001

FORM	PTO-1	449 (Modified)	A Bock	ket No.: 350013-71	Serial No.: 09/646,950
FOR A	PPLICA	ENTS AND PUBLICA ANT'S INFORMATION STATEMENT	PATENT 8	icants: Colin Watts	
			Filing	g Date: Sept. 25, 2000	Art Unit:
	ОТН	ER REFERENCES (I	ncluding Aut	hor, Date, Title, Pertine	nt Pages, Etc.)
Exr's. Ref. Bibliographic Data Inits.					
,	ВА	Multicatalytic Proteir	nase Complex	nhibition of the Proteolyti (Proteasome) by Substr OLOGICAL CHEMISTR	ate-Related Peptidyl
	BB		s; Synthesis a	nild; 1987; Oligodeoxynuo nd Enzymic Degradation 39-3542	
	ВС			fficient Synthesis of Olig ng H-Phosphonatae Appr	
	BD		te-backbone d		on from RNA by RNase H ROC. NATL. ACAD. SCI.
	BE	Human Immunodefi	ciency Virus T	CGP 53437, an Orally Bi ype 1 Protease with Pote CHEMOTHERAPY; pp. 2	ent Antiviral Activity;
	BF		igen Processii	r Cresswell; April 1994; <i>I</i> ng Possess a Promiscuol	Human transporters us Peptide-Binding Site;
	BG		ternucleotide	Linkages and their Speci	xynucleotides Containing ific Chemical Cleavage;
	ВН			1998; Caspase Activation ent; MOLECULAR PHAR	
	BI V		rsible Inhibitor	Demuth; 1994; <i>N,O-Diac</i> y rs <i>of Cysteine Proteinase</i> -685	
X-	BJ	Buttle, David J.; 199 649	4; Affinity Chr	omatography of Cysteine	e Peptidases; pp. 639-
	BK		aginyl Endope	eptidase; THE JOURNAL	cterization of Mammalian . OF BIOLOGICAL
Examin	er	<u> </u>		Date Considered	Í
				or not citation is in conform t in conformance and not	

	449 (Modified)		: 350013-71	Serial No.: 09/646,950
LIST OF PATI	ENTS AND PUBLICATIONS		Colin Watts	
ll .	ANT'S INFORMATION	ું હો	•	
DISCLOSURE	ANT'S INFORMATION E STATEMENT ( FB 2 2001	Fling Date:	Sept. 25, 2000	Art Unit:
	12	Date.	Эері. 20, 2000	Ait Oill.
OTL	IER REFERENCES (Includin	a Author D	ata Titla Partinar	ot Page Etc \
	•	ig Autiloi, D	ate, Tille, Fertillei	it rayes, Etc.)
Exr's. Ref. Inits.	Bibliographic Data		garia de la composição de	
CA	Chapman, Harold A.; 1998; ÇURRENT OPINION IMMU			C class II function;
CB V	Chen, Jinq-May, et al.; 1998 caspases, clostripain and gi FEBS Letters 441; pp. 361-	ngipains in a		
CC	Cohen, Gerald, et al.; 1990; function, diversity and evolu			
CD	Cosstick, Richard and Jose Oligonucleotides Containing No. 35; pp. 4693-4696			
CE	Cresswell, Peter; February Function; CELL, Vol. 84; pp		nt Chain Structure	and MHC Class II
. CF	Dàlton, J.P., et al.; 1995; As mansoni; PARASITOLOGY;			y in adult Schistosoma
CG	Davidson, Howard W. and C Specific Antigen by B Lympi pp <sub>y</sub> 85-92			
CH	Davidson, Howard W., et al. Processing of Membrane Ig in B Lymphocytes; THE JOU	G and Monov	/alent Antigen/Men	nbrane IgG Compleses
CI	Goodchild, John, et al., Aug réplication by antisense olig Vol. 85; pp. 5507-5511			
Cl	Hewitt, Eric W., et al.; 1997; Cathespin D in Tetanus Tox			uman Cathespin E and
СК	/Jäger, Alfred, et al.; 1988; C Binding to Polynucleotides;			
CL	Kembhavi, Asha A., et al.; 1 Seeds: Purification and Cha ARCHIVES OF BIOCHEMIS	racterization	by Use of Specific	Fluorometric Assay;
Examiner			Date Considered	
609. Draw line	itial if citation considered, who e through citation (i.e., <del>citatior</del>	a) if not in cor		
copy of this for	rm with next communication to	o applicant.		RECEIVED

FORM PTO-1	449 (Modified)	Docket No.:	350013-71	Seria 160.409(646,950	
FOR APPLICA	ENTS AND PUBLICATIONS ANT'S INFORMATION E STATEMENT	Applicants:	Colin Watts	O 26 201 E	
		Filing Date:	Sept. 25, 2000	Art Unit:	
	ER REFERENCES (Includin	g Author, Da	ate, Title, Pertinen	t Pages, Etc.)	
Exr's. Ref. Inits.	Bibliographic Data				
DA 1	/Kirśchke, Heidrun, et al.; 19	200 B C C	the state of the s		
DB	Krántz, Allen; 1994; <i>Peptidy</i> /Cýsteine Proteinases; pp. 6	56-671			
DC V	Kudo, Jiro, et al.; November /invariant γ-chain of class II h RESEARCH, Vol. 13, No. 24	istocompatib	ility antigens; NUC		
DD }	Ląńzavecchia, Antonio; 198 NATURE, Vol. 314, No. 501			etween T and B cells;	
DE Leitér, Josef M.E., et al.; 1990; Inhibition of influenza virus replication by phosphorothioate oligodeoxynucleotides; PROC. NATL. ACAD. SCI. USA 3430-3434					
DF /Lu/Jianyn and Herman van Halbeek; 1996; Complete H and C resonal assignments of a 21-amino acid glycopeptide prepared from human se fransferrin; CARBOHYDRATE RESEARCH; pp. 1-21					
DG	enzyl Alcohol Resin; J.				
DH V	/Makoff, Andrew J., et al.; Oc É. <i>Coli: Is Purification and P</i> /pp: 1043-1046				
DI	Manoury, Bénédicte, et al.; microbial antigen for class II	1998; An asp MHC preser	araginyl endopeptiontation; NATURE, V	dase processes a /ol. 396; pp. 695-699	
DJ Mikáelian, Ivan and Alain Sergeant; 1992; A general and fast method to multiple site directed mutations; NUCLEIC ACIDS RESEARCH, Vol. 20					
DK Nielsen, John, et al.; 1988; Synthesis and Characterization of Dinucleoside Phosphorodithioates; TETRAHEDRON LETTERS, Vol. 29, pp. 2911-2914					
DL	O'Sullivan, Deirdre M., et al.; 1986; Structure of the human la-associated invariant (γ)-chain gene: Identification of 5' sequences shared with major histocompatibility complex class II genes; PROC. NATL. ACAD. SCI. USA; pp. 4484-4488				
Examiner			Date Considered		
609. Draw line	itial if citation considered, whe e through citation (i.e., <del>citation</del> rm with next communication to	) if not in con	formance and not o		

RECEIVED

FEB 2 8 2001 TECH CENTER 1600/2900

FORM PTO-1449 (Modified)			Docket No.: 350013-71	Serial No. 99/646,950
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT			Applicants: Colin Watts	O TOTAL E
			Filing Date: Sept. 25, 2000	AN UNIT:
				FRANT & TRADE
	OTH	IER REFERENCES (Includin	g Author, Date, Title, Pertin	ent Pages, Etc.)
Exr's. nits.	Ref	Bibliographic Data		
	EA			
	EB	Palmer, James T., et al.; 199 Protease Inhibitors; J. MED.		ism-Based Cysteine
Я	EC l	Assembled, T Cell-Stimulato	s; 1997; Characterization of T ry MHC Class II-Peptide Con urface; THE AMERICAN ASS -553	nplexes from MHC Class
	ED		96; Essential Role for Cathep Processing and Peptide Load	
2 21	EE	Peptide Substrates Having in BIOPHYSICAL RESEARCH		HEMICAL AND 55-370
	EF	Şhaw, Elliott; 1994; <u>Peptidyl</u> <u>Proteinases;</u> METHODS IN I	<i>Diazomethanes as Inhibitors</i> ENZYMOLOGY; 649-656	of Cysteine and Serine
	EG	/Şhaw, Elliott and George D. Peptidyl; METHODS IN ENZ	J Green; 1981; <i>Inactivation o</i> YMOLOGY; pp. 820-826	f Thiol Proteases with
- % ·	€H		91; Modified deoxyoligonucleo serum; NUCLEIC ACIDS RE	
	EIV		de Aldehydes: Potent Inhibito IBODIES AND OTHER PRO	
	EJ	Substrates for Solid Support	37; Deoxyribonucleoside 3'-P ed Synthesis of Oligodeoxyri Triester Analogues; 1987; TE	bonucleotides and their
	EK		1997; Degradation of Mouse Influence of Major Histocom <sub>l</sub> I., Vol. 186; pp. 549-560	
Examiner			Date Considere	ed

<sup>\*</sup> Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. ¶ 609. Draw line through citation (i.e., eitation) if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

FORM PTO-1449 (Modified)			Docket No.: 350013-7	71	Serial No.POD/64	6,950	
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT			Applicants: Colin Wa	tts	FEB 26 2001	मितः क्ष	
		·	Filing Date: Sept. 25,	2000	Art Unit:		
	OTI	IED DEFEDENCES (I I I'.	A. the Detection	D4!	4 Daniel Frau		
F.LJ.		IER REFERENCES (Includin	g Author, Date, Title,	Pertiner	it Pages, Etc.)	111 111	
Exr's. Inits.	Ref						
	$\mid$ FA $_{\lor}$	/Watts, Colin; 1997; Capture Presentation on MHC Molec	ules; ANNU. REV. IMN	MUNOL.;	pp. 821-850		
	FB			Mann; 1993; Peptide Chloromethyl Ketones as ENZYMOLOGY, Vol. 222; pp. 503-513			
	FC $\sqrt{}$	Woods, Andrea, et al.; July Restricted T Cell Responses 181					
	FD	Yamamoto, Ken, et al., July Histocompatibility Leukocyte Antigen Recognition by T Ce Vol. 180, pp. 165-171	Antigen (HLA) Class I	l and Mo	use CD4 Molecule		
,	FE	Cantorna, Margherita T., et a Progression of Arthritis in Mu FOR NUTRITIONAL SCIEN	urine Models of Human				
	FF/	/ Kumar, Vipin, et al.; May 1997; Regulatory T Cells Specific for the Same Framework 3 Region of the Vβ8.2 Chain Are Involved in the Control of Collagen II-induced Arthritis and Experimental Autoimmune Encephalomyelitis; J. EXP. MED., Vol. 185; pp. 1725-1733					
-	FG	Sarin, Prem S., et al.; Octob syndrome virus by oligodeox ACAD. SCI. USA, Vol. 85; p 86, pp. 7790-7794].	ynucleoside methylpho	sphonat	tes; PROC. NATL.		
*	FH	Tang, Jin yan, et al.; 1993; S phosphorothioates: propertie Vol. 21; pp. 2729-2735				RCH,	
	FI	Bogyo, Matthew and Hidde I Blood; NEWS AND VIEWS;		998; <i>A P</i>	rotease Draws Firs	st	
Examin	er	L	Date Co	nsidered			
		itial if citation considered, whe				•••	
		e through citation (i.e., <del>citation</del> rm with next communication to		and not	considered. Include	de	

RECEIVED

FEB 2 8 2001

FORM	PTO-1	449 (Modified)	Docket No.: 350013-71	Serial No.: 09/646,950		
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT			Applicants: Colin Watts	PB 2 8		
			Filing Date: Sept. 25, 2000	Art Unit:		
				E 10133		
	OTH	IER REFERENCES (Includin	ng Author, Date, Title, Pertine	nt Pages, Etc.)		
Exr's. Inits.	Ref	Bibliographic Data				
	GA		997; Antigen endocytosis and properties $eta$ absence of the $\log lpha / \lg eta$ dimer			
	GB		pression of tetanus toxin fragme codons; NUCLEIC ACIDS RE			
1	GC	Makoff, A.J. and M.D. Oxer; 1991; High level heterologous expression in E.coli using mutant forms of the lac promoter, NUCLEIC ACIDS RESEARCH, Vol. 19; pp 2417-2421				
	GD	Simitsek, Phaedra D., et al.; June 1995; Modulation of Antigen Processing by Bound Antibodies Can Boost or Suppress Class II Major Histocompatibility Complex Presentation of Different T Cell Determinants; J. EXP. MED., Vol. 181; pp.1957-1963				
	GE	Strubin, Michel; et al.; 1984; The complete sequence of the mRNA for the HLA-DI associated invariant chain reveals a polypeptide with an unusual transmembrane polarity; THE EMBO JOURNAL, Vol. 3; pp. 869-872				
	GF Peptimmune and Peptide Therapeutics collaborate on asthma and autoimmundiseases; PHARMACEUTICAL BUSINESS NEWS, March 25, 1998					
	GG					
	GH					
	GI					
	GJ					
	GH					
Examiner			Date Considered			
* Exam	iner: In	nitial if citation considered, whe	ether or not citation is in conform	nance with M.P.E.P. ¶		

\* Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. ¶ 609. Draw line through citation (i.e., citation) if not in conformance and not considered. Include copy of this form with next communication to applicant.

Page 7of 7

RECEIVED

FFB 2 8 2001

TECH CENTER 1600/2900